Beijing Airdoc Technology Co has a Cash Ratio of 14.70. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Beijing Airdoc Technology Co's Cash Ratio or its related term are showing as below:
HKSE:02251'
s Cash Ratio Range Over the Past 10 Years
Min: 0.44 Med: 14.7 Max: 32.93
Current: 14.7
During the past 5 years, Beijing Airdoc Technology Co's highest Cash Ratio was 32.93. The lowest was 0.44. And the median was 14.70.
HKSE:02251's Cash Ratio is ranked better than 98.81% of 673
companies
in the Healthcare Providers & Services industry
Industry Median: 0.57
vs HKSE:02251: 14.70
Beijing Airdoc Technology Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beijing Airdoc Technology Co's Cash Ratio
For the Health Information Services subindustry, Beijing Airdoc Technology Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Airdoc Technology Co's Cash Ratio Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Beijing Airdoc Technology Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Airdoc Technology Co's Cash Ratio falls into.
Beijing Airdoc Technology Co Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Airdoc Technology Co (HKSE:02251) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Beijing Airdoc Technology Co Cash Ratio Related Terms
Thank you for viewing the detailed overview of Beijing Airdoc Technology Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue principally from the provision of AI-based software solutions, sales of hardware devices, and other services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02251 has been successfully added to your 